• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于聚乳酸-羟基乙酸共聚物纳米颗粒的剂型穿越血脑屏障用于药物递送:从研发到符合药品生产质量管理规范

PLGA Nanoparticle-Based Formulations to Cross the Blood-Brain Barrier for Drug Delivery: From R&D to cGMP.

作者信息

Zhi Kaining, Raji Babatunde, Nookala Anantha R, Khan Mohammad Moshahid, Nguyen Xuyen H, Sakshi Swarna, Pourmotabbed Tayebeh, Yallapu Murali M, Kochat Harry, Tadrous Erene, Pernell Shelby, Kumar Santosh

机构信息

Plough Center for Sterile Drug Delivery Solutions, University of Tennessee Health Science Center, 208 South Dudley Street, Memphis, TN 38163, USA.

Covance Inc., Kinsman Blvd, Madison, WI 53704, USA.

出版信息

Pharmaceutics. 2021 Apr 6;13(4):500. doi: 10.3390/pharmaceutics13040500.

DOI:10.3390/pharmaceutics13040500
PMID:33917577
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8067506/
Abstract

The blood-brain barrier (BBB) is a natural obstacle for drug delivery into the human brain, hindering treatment of central nervous system (CNS) disorders such as acute ischemic stroke, brain tumors, and human immunodeficiency virus (HIV)-1-associated neurocognitive disorders. Poly(lactic--glycolic acid) (PLGA) is a biocompatible polymer that is used in Food and Drug Administration (FDA)-approved pharmaceutical products and medical devices. PLGA nanoparticles (NPs) have been reported to improve drug penetration across the BBB both in vitro and in vivo. Poly(ethylene glycol) (PEG), poly(vinyl alcohol) (PVA), and poloxamer (Pluronic) are widely used as excipients to further improve the stability and effectiveness of PLGA formulations. Peptides and other linkers can be attached on the surface of PLGA to provide targeting delivery. With the newly published guidance from the FDA and the progress of current Good Manufacturing Practice (cGMP) technologies, manufacturing PLGA NP-based drug products can be achieved with higher efficiency, larger quantity, and better quality. The translation from bench to bed is feasible with proper research, concurrent development, quality control, and regulatory assurance.

摘要

血脑屏障(BBB)是药物进入人脑的天然障碍,阻碍了对中枢神经系统(CNS)疾病的治疗,如急性缺血性中风、脑肿瘤和人类免疫缺陷病毒(HIV)-1相关神经认知障碍。聚乳酸-乙醇酸共聚物(PLGA)是一种生物相容性聚合物,用于食品药品监督管理局(FDA)批准的药品和医疗器械。据报道,PLGA纳米颗粒(NPs)在体外和体内均可提高药物透过血脑屏障的能力。聚乙二醇(PEG)、聚乙烯醇(PVA)和泊洛沙姆(普朗尼克)被广泛用作辅料,以进一步提高PLGA制剂的稳定性和有效性。肽和其他连接体可连接在PLGA表面,以实现靶向递送。随着FDA最新发布的指南以及当前良好生产规范(cGMP)技术的进步,可以更高效率、更大规模和更高质量地生产基于PLGA NPs的药品。通过适当的研究、同步开发、质量控制和监管保证,从实验室到临床的转化是可行的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd27/8067506/28ec58e3b61d/pharmaceutics-13-00500-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd27/8067506/41cc46d4bd58/pharmaceutics-13-00500-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd27/8067506/28ec58e3b61d/pharmaceutics-13-00500-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd27/8067506/41cc46d4bd58/pharmaceutics-13-00500-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd27/8067506/28ec58e3b61d/pharmaceutics-13-00500-g002.jpg

相似文献

1
PLGA Nanoparticle-Based Formulations to Cross the Blood-Brain Barrier for Drug Delivery: From R&D to cGMP.基于聚乳酸-羟基乙酸共聚物纳米颗粒的剂型穿越血脑屏障用于药物递送:从研发到符合药品生产质量管理规范
Pharmaceutics. 2021 Apr 6;13(4):500. doi: 10.3390/pharmaceutics13040500.
2
Intracisternal administration of tanshinone IIA-loaded nanoparticles leads to reduced tissue injury and functional deficits in a porcine model of ischemic stroke.在猪缺血性中风模型中,脑池内给予载有丹参酮IIA的纳米颗粒可减轻组织损伤和功能缺损。
IBRO Neurosci Rep. 2021 Jan 5;10:18-30. doi: 10.1016/j.ibneur.2020.11.003. eCollection 2021 Jun.
3
Effects of surface modification of PLGA-PEG-PLGA nanoparticles on loperamide delivery efficiency across the blood-brain barrier.PLGA-PEG-PLGA 纳米粒表面修饰对洛哌丁胺透过血脑屏障递送效率的影响。
J Biomater Appl. 2013 Mar;27(7):909-22. doi: 10.1177/0885328211429495. Epub 2011 Dec 29.
4
Surfactants influence polymer nanoparticle fate within the brain.表面活性剂影响聚合物纳米颗粒在大脑中的命运。
Biomaterials. 2021 Oct;277:121086. doi: 10.1016/j.biomaterials.2021.121086. Epub 2021 Aug 28.
5
Brain targeting with surface-modified poly(D,L-lactic-co-glycolic acid) nanoparticles delivered via carotid artery administration.经颈动脉给药的表面修饰聚(D,L-乳酸-共-乙醇酸)纳米粒脑靶向给药。
Eur J Pharm Biopharm. 2011 Jan;77(1):84-8. doi: 10.1016/j.ejpb.2010.11.002. Epub 2010 Nov 11.
6
Engineering PLGA nano-based systems through understanding the influence of nanoparticle properties and cell-penetrating peptides for cochlear drug delivery.通过了解纳米颗粒特性和穿透细胞肽对耳蜗药物传递的影响来设计基于 PLGA 的纳米系统。
Int J Pharm. 2017 Oct 30;532(1):55-65. doi: 10.1016/j.ijpharm.2017.08.084. Epub 2017 Sep 7.
7
Luminescent PLGA Nanoparticles for Delivery of Darunavir to the Brain and Inhibition of Matrix Metalloproteinase-9, a Relevant Therapeutic Target of HIV-Associated Neurological Disorders.载阿扎那韦的发光 PLGA 纳米粒递药系统通过抑制基质金属蛋白酶-9 治疗 HIV 相关神经障碍
ACS Chem Neurosci. 2021 Nov 17;12(22):4286-4301. doi: 10.1021/acschemneuro.1c00436. Epub 2021 Nov 2.
8
Comparative evaluation of the degree of pegylation of poly(lactic-co-glycolic acid) nanoparticles in enhancing central nervous system delivery of loperamide.聚(乳酸-共-乙醇酸)纳米粒的聚乙二醇化程度对增强洛哌丁胺中枢神经系统递送的比较评价。
J Pharm Pharmacol. 2013 Oct;65(10):1473-81. doi: 10.1111/jphp.12125. Epub 2013 Aug 1.
9
Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile.用于静脉注射的载多西他赛聚乳酸-羟基乙酸共聚物和聚乳酸-羟基乙酸共聚物-聚乙二醇纳米粒:药代动力学和生物分布特征
Int J Nanomedicine. 2017 Jan 27;12:935-947. doi: 10.2147/IJN.S121881. eCollection 2017.
10
Potential use of polymeric nanoparticles for drug delivery across the blood-brain barrier.聚合物纳米粒用于血脑屏障药物递送的潜力。
Curr Med Chem. 2013;20(17):2212-25. doi: 10.2174/0929867311320170006.

引用本文的文献

1
Revamping Parkinson's disease therapy using PLGA-based drug delivery systems.利用基于聚乳酸-羟基乙酸共聚物的药物递送系统改进帕金森病治疗方法。
NPJ Parkinsons Dis. 2025 Aug 20;11(1):248. doi: 10.1038/s41531-025-01081-1.
2
Preparation of surface-modified PLGA nanoparticles containing carbon quantum dots: insights from C6 cell line assays.含碳量子点的表面改性聚乳酸-羟基乙酸共聚物纳米颗粒的制备:来自C6细胞系检测的见解
Nanomedicine (Lond). 2025 Jun;20(12):1403-1416. doi: 10.1080/17435889.2025.2504322. Epub 2025 May 20.
3
PLGA-Encapsulated Elvitegravir and Curcumin Modulates ART Penetration, Oxidative Stress, and Inflammation.

本文引用的文献

1
Epigallocatechin-3-gallate PEGylated poly(lactic-co-glycolic) acid nanoparticles mitigate striatal pathology and motor deficits in 3-nitropropionic acid intoxicated mice.没食子儿茶素没食子酸酯聚乙二醇化聚(乳酸-共-乙醇酸)纳米粒子减轻 3-硝基丙酸中毒小鼠纹状体病理学和运动缺陷。
Nanomedicine (Lond). 2021 Jan;16(1):19-35. doi: 10.2217/nnm-2020-0239. Epub 2021 Jan 7.
2
Challenges in Biomaterial-Based Drug Delivery Approach for the Treatment of Neurodegenerative Diseases: Opportunities for Extracellular Vesicles.基于生物材料的药物递送方法在神经退行性疾病治疗中的挑战:细胞外囊泡的机遇
Int J Mol Sci. 2020 Dec 25;22(1):138. doi: 10.3390/ijms22010138.
3
聚乳酸-羟基乙酸共聚物包裹的埃替格韦与姜黄素可调节抗逆转录病毒治疗的渗透、氧化应激和炎症反应。
Brain Sci. 2025 Mar 21;15(4):328. doi: 10.3390/brainsci15040328.
4
Preparation and Characterization of Mitochondrial-Targeted Nitronyl Nitroxide Loaded PLGA Nanoparticles for Brain Injury Induced by Hypobaric Hypoxia in Mice.用于小鼠低压缺氧诱导脑损伤的线粒体靶向氮氧自由基负载聚乳酸-羟基乙酸共聚物纳米粒的制备与表征
Int J Nanomedicine. 2025 Apr 1;20:3999-4020. doi: 10.2147/IJN.S507315. eCollection 2025.
5
Temperature-Dependent Aggregation of Tau Protein Is Attenuated by Native PLGA Nanoparticles Under in vitro Conditions.在体外条件下,天然聚乳酸-羟基乙酸共聚物纳米颗粒可减弱tau蛋白的温度依赖性聚集。
Int J Nanomedicine. 2025 Feb 14;20:1999-2019. doi: 10.2147/IJN.S494104. eCollection 2025.
6
Formulation and characterization of CMPI nanoparticles for enhanced targeting of brain nicotinic receptors by positive allosteric modulator.用于通过正变构调节剂增强脑烟碱受体靶向性的CMPI纳米颗粒的制备与表征
Sci Rep. 2025 Feb 6;15(1):4487. doi: 10.1038/s41598-024-80935-9.
7
Targeting Brain Drug Delivery with Macromolecules Through Receptor-Mediated Transcytosis.通过受体介导的转胞吞作用利用大分子靶向脑药物递送。
Pharmaceutics. 2025 Jan 15;17(1):109. doi: 10.3390/pharmaceutics17010109.
8
Auranofin-loaded PLGA Nanoparticles for Neuroprotection against Aluminium-induced Alzheimer's Disease.负载金诺芬的聚乳酸-羟基乙酸共聚物纳米颗粒对铝诱导的阿尔茨海默病的神经保护作用
Curr Pharm Des. 2025 Jan 17. doi: 10.2174/0113816128336703241202182209.
9
Comparison of Drug Delivery Systems with Different Types of Nanoparticles in Terms of Cellular Uptake and Responses in Human Endothelial Cells, Pericytes, and Astrocytes.不同类型纳米颗粒的药物递送系统在人内皮细胞、周细胞和星形胶质细胞中的细胞摄取及反应比较
Pharmaceuticals (Basel). 2024 Nov 22;17(12):1567. doi: 10.3390/ph17121567.
10
Curcumin-Loaded Gelatin Nanoparticles Cross the Blood-Brain Barrier to Treat Ischemic Stroke by Attenuating Oxidative Stress and Neuroinflammation.姜黄素载药明胶纳米粒通过减轻氧化应激和神经炎症治疗缺血性脑卒中。
Int J Nanomedicine. 2024 Nov 10;19:11633-11649. doi: 10.2147/IJN.S487628. eCollection 2024.
A blood-brain barrier overview on structure, function, impairment, and biomarkers of integrity.
血脑屏障的结构、功能、损伤及完整性生物标志物概述。
Fluids Barriers CNS. 2020 Nov 18;17(1):69. doi: 10.1186/s12987-020-00230-3.
4
Functionalized PLGA nanoparticles prepared by nano-emulsion templating interact selectively with proteins involved in the transport through the blood-brain barrier.功能化的 PLGA 纳米颗粒通过纳米乳液模板制备,与参与血脑屏障转运的蛋白质选择性相互作用。
Eur J Pharm Biopharm. 2020 Nov;156:155-164. doi: 10.1016/j.ejpb.2020.09.003. Epub 2020 Sep 11.
5
Drug-encapsulated blend of PLGA-PEG microspheres: in vitro and in vivo study of the effects of localized/targeted drug delivery on the treatment of triple-negative breast cancer.载药 PLGA-PEG 微球混合物:局部/靶向药物递送治疗三阴性乳腺癌的体内外研究。
Sci Rep. 2020 Aug 25;10(1):14188. doi: 10.1038/s41598-020-71129-0.
6
Chitosan-coated PLGA nanoparticles for the nasal delivery of ropinirole hydrochloride: In vitro and ex vivo evaluation of efficacy and safety.壳聚糖包覆的 PLGA 纳米粒经鼻递给药盐酸罗匹尼罗:药效学和安全性的体外与离体评价。
Int J Pharm. 2020 Nov 15;589:119776. doi: 10.1016/j.ijpharm.2020.119776. Epub 2020 Aug 17.
7
Real-time monitoring of quality attributes by in-line Fourier transform infrared spectroscopic sensors at ultrafiltration and diafiltration of bioprocess.在生物工艺超滤和透析过程中,通过在线傅里叶变换红外光谱传感器实时监测质量属性。
Biotechnol Bioeng. 2020 Dec;117(12):3766-3774. doi: 10.1002/bit.27532. Epub 2020 Aug 18.
8
PLGA Nanoparticles for Nose to Brain Delivery of Clonazepam: Formulation, Optimization by 32 Factorial Design, In Vitro and In Vivo Evaluation.PLGA 纳米粒经鼻腔递送至脑内给予氯硝西泮:配方、32 析因设计优化、体外与体内评价。
Curr Drug Deliv. 2021;18(6):805-824. doi: 10.2174/1567201817666200708115627.
9
Therapeutic Delivery to the Brain via the Lymphatic Vasculature.通过淋巴管系统向大脑进行治疗性给药。
Nano Lett. 2020 Jul 8;20(7):5415-5420. doi: 10.1021/acs.nanolett.0c01806. Epub 2020 Jun 16.
10
An Elvitegravir Nanoformulation Crosses the Blood-Brain Barrier and Suppresses HIV-1 Replication in Microglia.一种埃替拉韦纳米制剂可穿透血脑屏障并抑制小神经胶质细胞中的 HIV-1 复制。
Viruses. 2020 May 20;12(5):564. doi: 10.3390/v12050564.